Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New method of administering anti-cancer drug may be more effective, safer

19.05.2005


A novel way of administering an anti-cancer drug to bone-marrow transplant patients using continuous infusion may be more effective and safer than the method currently used, new study findings indicate.



The new method achieves more predictable, stable drug levels in patients than the current method and could eventually allow doctors to more accurately adjust doses to accommodate individual differences in metabolism, thus increasing treatment effectiveness while avoiding side effects, said University of North Carolina at Chapel Hill researchers.

The findings were presented at the 2005 annual meeting of the American Society of Clinical Oncology, held May 13 through 17 in Orlando, Fla. The drug busulfan is used in leukemia patients to kill cancerous cells before bone-marrow transplant. Currently, it is administered in intermittent intravenous doses, typically via two-hour infusions of the drug every six hours. Previous studies have reported that frequent dose adjustments are needed to maintain the desired level of drug in patients and that metabolism of the drug varies from patient to patient.


"The new continuous-infusion method achieved more predictable levels of the drug than does the usual delivery method," said Dr. Thomas C. Shea, professor of medicine at UNC, director of the Bone Marrow Transplant Program at the UNC Health Care System and a member of the UNC Lineberger Comprehensive Cancer Center.

"In the relatively small number of patients tested with continuous infusion, there didn’t appear to be a change in concentration or clearance of the drug during the 90-hour infusion period."

In 12 patients scheduled for bone marrow transplants, UNC researchers administered a single busulfan test dose of 0.8 mg/kg adjusted body weight over two hours. Blood concentrations of the drug were measured every two hours for eight hours following that test dose.

Then researchers administered busulfan by the novel method - patients received a continuous IV infusion for 90 hours. Blood concentrations of the drug were monitored every six hours.

With the new method, the test dose predicted the patients’ blood levels of the drug with less than 10 percent variability.

In a separate study using a test dose and the standard intermittent delivery method, the patients metabolized the drug more slowly as the intermittent doses continued. By the 13th and final dose, on average the variability between the test-dose prediction and the actual levels had grown to more than 20 percent.

The new method may prevent side effects and increase effectiveness by maintaining a more consistent level of drug in the blood and avoiding extreme highs and lows, Shea said. "We hope this novel delivery method will be safer, and we hope it will allow us to give more total drug, which will do a better job by killing more cancer cells."

In the patients’ studied, side effects were similar to those seen in current treatment. "This prolonged infusion looks like it’s at least as safe as what we’ve been doing before," Shea said.

Because patients appear to metabolize busulfan more predictably when receiving it by continuous infusion, doctors may be able to more effectively tailor doses to individuals. "This novel delivery method may give us a new opportunity for consistent and targeted dosing for individual patients," Shea said.

Shea and his colleagues are developing a study of such tailored dosing and hope to open a clinical trial by the end of the summer.

Leslie H. Lang | EurekAlert!
Further information:
http://www.med.unc.edu

More articles from Studies and Analyses:

nachricht The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung

nachricht A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>